KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2016 - 2025)

Vertex Pharmaceuticals has reported Change in Acquisitions & Divestments over the past 17 years, most recently at -$4.8 billion for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at -$4.8 billion for Q4 2025, down 428.01% from a year ago — trailing twelve months through Dec 2025 was $16.0 million (down 99.64% YoY), and the annual figure for FY2025 was $16.0 million, down 99.64%.
  • Change in Acquisitions & Divestments for Q4 2025 was -$4.8 billion at Vertex Pharmaceuticals, down from $1.3 billion in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for VRTX hit a ceiling of $1.8 billion in Q2 2025 and a floor of -$4.8 billion in Q4 2025.
  • Median Change in Acquisitions & Divestments over the past 5 years was $239.8 million (2023), compared with a mean of $354.7 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: skyrocketed 5395.24% in 2021 and later crashed 428.01% in 2025.
  • Vertex Pharmaceuticals' Change in Acquisitions & Divestments stood at $47.2 million in 2021, then soared by 1849.15% to $920.0 million in 2022, then decreased by 19.13% to $744.0 million in 2023, then surged by 96.26% to $1.5 billion in 2024, then crashed by 428.01% to -$4.8 billion in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were -$4.8 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.8 billion (Q2 2025) per Business Quant data.